Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 9/20 | 0.68 |
| ▸ | MMP2 | P08253 | 6/20 | 0.68 |
| ▸ | MMP14 | P50281 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978134 | 0.89 | MMP13 (0.65) | MMP13MMP2MMP14KDM4EALDH1A1 | |
| SCHEMBL29900508 | 0.89 | MMP13 (0.65) | MMP13MMP2MMP14KDM4EALDH1A1 | |
| SCHEMBL31010837 | 0.87 | MMP13 (0.63) | MMP13MMP2MMP14KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL30458283 | 0.87 | MMP13 (0.63) | MMP13MMP2MMP14KDM4EALDH1A1 | |
| SCHEMBL1569349 | 0.84 | NAMPT (0.64) | MMP13MMP2MMP14NAMPTHRH4 | |
| SCHEMBL10815601 | 0.82 | KDM5A (0.54) | MMP13MMP2MMP14KDM4EALDH1A1 | |
| SCHEMBL15642864 | 0.81 | MMP13 (1.00) | MMP13MMP2MMP14KDM4EALDH1A1 | |
| SCHEMBL7682150 | 0.81 | LMNA (0.52) | MMP13MMP2MMP14KDM4EALDH1A1 | |
| SCHEMBL3598543 | 0.81 | MMP13 (0.54) | MMP13MMP2MMP14KDM4EALDH1A1 | |
| SCHEMBL15642502 | 0.80 | MMP13 (1.00) | MMP13MMP2MMP14KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024182382-A1 | 4,5-FUSED BICYCLIC PYRROLIDINE AND 4,5-FUSED BICYCLIC PYRROLIDINONE COMPOUNDS | CYTEIR THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11884668-B1 | Substituted pyrido[3′,4′:4,5]pyrrolo[2,3-c]quinolines as CK2 inhibitors | King Faisal University (SA) | 2024-01-30 | — | — | US | disclosed |
| US-11845724-B2 | USP30 inhibitors and uses thereof | VINCERE BIOSCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-115038688-A | USP30 inhibitors and uses thereof | 文森雷生物科学股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-4028385-A1 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021050992-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021050992-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| US-9896459-B2 | Azaindoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-20 | — | — | US | disclosed |
| US-7405210-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | OSI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7402672-B2 | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon | AVENTIS PHARMACEUTICALS INC. (US) | 2008-07-22 | — | — | US | disclosed |
| WO-2008067481-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | BRADLEY STUART E | 2007-10-18 | — | — | US | disclosed |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | BRADLEY STUART E | 2007-10-18 | — | — | US | disclosed |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | BRADLEY STUART E | 2007-10-18 | — | — | US | disclosed |
| EP-1636224-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | Prosidion Limited (GB) | 2006-03-22 | — | — | EP | disclosed |
| US-20050261272-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2005-11-24 | — | — | US | disclosed |
| US-20050131012-A1 | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon | AVENTIS PHARMACEUTICALS INC. (US) | 2005-06-16 | — | — | US | disclosed |
| WO-2004104001-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | PROSIDION LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131012-A1 | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon | CSNK2A3, PACSIN2, CSNK1G3 | MMP13 1875/4885MMP2 3453/4885MMP14 2719/4885 |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | PYGL, PYGM, PYGB | MMP13 1830/4885MMP2 572/4885MMP14 2109/4885 |
| US-11884668-B1 | Substituted pyrido[3′,4′:4,5]pyrrolo[2,3-c]quinolines as CK2 inhibitors | CSNK1A1L, CCNL2, CDKL3 | MMP13 4400/4885MMP2 3826/4885MMP14 4677/4885 |
| US-20050261272-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PYGL, PYGM, PYGB | MMP13 1830/4885MMP2 572/4885MMP14 2109/4885 |
| US-11845724-B2 | USP30 inhibitors and uses thereof | USP30, USP28, USP1 | MMP13 3472/4885MMP2 3037/4885MMP14 2597/4885 |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | MMP13 3472/4885MMP2 3037/4885MMP14 2597/4885 |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | MMP13 3472/4885MMP2 3037/4885MMP14 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.